[Treatment of the Parkinson syndrome with amantadine].
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000150:complications; D003072:Cognition Disorders / Q000188:drug therapy; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D010276:Parasympatholytics / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D013035:Spasm / Q000188:drug therapy; D013064:Speech Disorders / Q000188:drug therapy; D014202:Tremor / Q000188:drug therapy
D010276:Parasympatholytics; D004295:Dihydroxyphenylalanine; D000547:Amantadine
die Behandlung des Parkinson-Syndroms mit Amantadin.